May 12 (Reuters) - Pharming Group NV :
Q1 REVENUES INCREASED 7% YOY TO $46.6 MILLION
LENIOLISIB LAUNCH ON TRACK FOR Q1 2023 FOLLOWING PREVIOUSLY ANNOUNCED POSITIVE PIVOTAL DATA
Q1 OPERATING PROFIT DECREASED TO US$2.8 MILLION (Q1 2021: US$6.3 MILLION),
Q1 NET PROFIT OF US$3.5 MILLION DECREASED 59% (Q1 2021: US$8.5 MILLION).
EXPECT TO BE ABLE TO LAUNCH LENIOLISIB IN US, SUBJECT TO REGULATORY APPROVAL, IN Q1 2023, FOLLOWED BY LAUNCHES IN EU MARKETS, SUBJECT TO REGULATORY APPROVAL, STARTING IN H2 2023.
FOR REMAINDER OF 2022, COMPANY ANTICIPATES: * SINGLE DIGIT GROWTH IN GROUP REVENUES FROM RUCONEST® SALES,
OUTLOOK SUBJECT TO PROGRESSION OF COVID-19 PANDEMIC
QUARTERLY FLUCTUATIONS IN REVENUES ARE EXPECTED
SUBMISSION OF LENIOLISIB REGULATORY FILINGS TO FDA AND EMA, WITH COMMERCIAL LAUNCH EXPECTED FROM EARLY Q1 2023 ONWARDS, SUBJECT TO REGULATORY APPROVALS
Source text for Eikon: [ID:nPrem7JBZa] Further company coverage: [PHAR.AS]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))